Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin’s Lymphoma

Age 18-80; Karnofsky PS >= 70% that have persistent or recurrent DLBCL; must have received 1-3 prior treatment regimens, inc/ induction chemotherapy and <= 2 salvage regimens; monoclonal antibody therapy and local radiation will not be counted as prior therapies; must have chemosensitive disease as demonstrated by response to induction or salvage chemotherapy by achieving a >= 50% reduction in estimated lymph node volume and a reduction in lymph node axial diameter to <= 3 cm OR >= 75% reduction in estimated lymph node volume; must also have <= 20% bone marrow involvement after most recent salvage therapy.